



Pseudotyped VSV-SARS-CoV-1 S-ΔG-Luciferase (COV-PSV20)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	Pseudotyped VSV-SARS-CoV-1 S-ΔG-Luciferase encodes the antigenomic-sense (or positive-sense) RNA of a replicaton-restricted recombinant vesicular stomatitis virus (rVSV) in which the glycoprotein (G) gene has been replaced with SARS-CoV-1 spike protein. Because the infectivity of Pseudotyped VSV-SARS-CoV-1 S-ΔG-Luciferase is restricted to a single round of replication, the pseudotypes can be handled using BSL-2 containment practices. The pseudotype VSV particles encode Luciferase together with the VSV nucleocapsid (N), phosphoprotein (P), glycoprotein (G), and large polymerase subunit (L) in their pVSV-ΔG vector. When the VSV pseudovirus infect the target cells, Luciferase expression is proportional to the number of cells that were infected.
Antigen Description	SARS-CoV-1 Envelope Protein
Species	SARS-CoV-1
Applications	Dilute the SARS-CoV-2 pseudotyped virus to 1.3E+04 TCID50/ml in complete DMEM. We recommended to use 50 μl of the diluted pseudotyped virus per 2E+04 Huh-7 cells for in vitro assay. Due to differences in cell status, the best infection conditions and MOI should be determined by the end user. The virus can be diluted with cell culture medium if needed.
Size	2×100 μl, 5×100 μl, 10×100 μl
Storage	Store at -80°C . Multiple freeze/thaw cycles not recommended. When using the virus, transfer the virus from the -80°C refrigerator and melt it in an ice bath.
Ship	Frozen on dry ice

BACKGROUND

Keywords

SARS-CoV-1; Coronavirus; SARS-CoV; SARS-CoV-1 Envelope Protein; SARS-CoV-1 Envelope glycoprotein; SARS-CoV-1 glycoprotein; Severe Acute Respiratory Syndrome; Severe Acute Respiratory Syndrome-1; Severe Acute Respiratory Syndrome glycoprotein; Severe Acute Respiratory Syndrome-1 glycoprotein; SARS-CoV-1 Pseudovirus; SARS-CoV Pseudovirus; SARS Pseudovirus
